{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:45:36Z","timestamp":1760028336172,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41371-018-0139-x","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T10:07:08Z","timestamp":1544004428000},"page":"167-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone\u2013renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design"],"prefix":"10.1038","volume":"33","author":[{"given":"Giacomo","family":"Rossitto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Ceolotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa Maria","family":"Seccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-0931","authenticated-orcid":false,"given":"Gian Paolo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"key":"139_CR1","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293\u20132300.","journal-title":"J Am Coll Cardiol"},{"key":"139_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The managent of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889\u2013916.","journal-title":"J Clin Endocrinol Metab"},{"key":"139_CR3","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","volume":"371","author":"S Douma","year":"2008","unstructured":"Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921\u20136.","journal-title":"Lancet"},{"key":"139_CR4","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1210\/jc.2003-032179","volume":"89","author":"O Olivieri","year":"2004","unstructured":"Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab. 2004;89:4221\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"139_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"GP Rossi","year":"2013","unstructured":"Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62:62\u20139.","journal-title":"Hypertension"},{"key":"139_CR6","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. British Hypertension Society\u2019s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"139_CR7","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. ESC Scientific Document Group. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"139_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00424-009-0656-0","volume":"458","author":"J Loffing","year":"2009","unstructured":"Loffing J, Korbmacher C. Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC). Pflug Arch. 2009;458:111\u201335.","journal-title":"Pflug Arch"},{"issue":"Suppl 2","key":"139_CR9","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1097\/00005344-198507002-00015","volume":"7","author":"JB Michel","year":"1985","unstructured":"Michel JB, Dussaule JC, Alhenc-Gelas F, Corvol P, Menard J. Can inhibition of the renin-angiotensin system have a cardioprotective effect? J Cardiovasc Pharmacol. 1985;7(Suppl 2):S75\u201379.","journal-title":"J Cardiovasc Pharmacol"},{"key":"139_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrendo.2016.196","volume":"13","author":"GP Rossi","year":"2017","unstructured":"Rossi GP, Ceolotto G, Caroccia B, Lenzini L. Genetic screening in arterial hypertension. Nat Rev Endocrinol. 2017;13:289\u201398.","journal-title":"Nat Rev Endocrinol"},{"key":"139_CR11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1515\/cclm-2015-1094","volume":"54","author":"GP Rossi","year":"2016","unstructured":"Rossi GP, Ceolotto G, Rossitto G, Seccia TM, Maiolino G, Berton C, et al. Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clin Chem Lab Med. 2016;54:1441\u201350.","journal-title":"Clin Chem Lab Med"},{"key":"139_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1161\/HYPERTENSIONAHA.109.139832","volume":"55","author":"GP Rossi","year":"2010","unstructured":"Rossi GP, Seccia TM, Palumbo G, Belfiore A, Bernini G, Caridi G, et al. Primary Aldosteronism in the Prevalence in hYpertension (PAPY) Study Investigators. Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension. 2010;55:83\u201389.","journal-title":"Hypertension"},{"key":"139_CR13","first-page":"19","volume":"23","author":"G Maiolino","year":"2017","unstructured":"Maiolino G, Rossitto G, Bisogni V, Cesari M, Seccia TM, Plebani M, et al. PAPY Study Investigators. Quantitative value of aldosterone-renin ratio for detection of aldosterone-producing adenoma: the aldosterone-renin ratio for primary aldosteronism (AQUARR) study. J Am Heart Assoc. 2017;23:19\u201323.","journal-title":"J Am Heart Assoc"},{"key":"139_CR14","doi-asserted-by":"publisher","unstructured":"Seccia TM, Caroccia B, Gomez-Sanchez EP, Gomez-Sanchez CE, Rossi GP. The biology of normal zona glomerulosa and aldosterone-producing adenoma: pathological implications. Endocr Rev. 2018. \n                    https:\/\/doi.org\/10.1210\/er.2018-00060","DOI":"10.1210\/er.2018-00060"},{"key":"139_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/HJH.0000000000001686","volume":"36","author":"GP Rossi","year":"2018","unstructured":"Rossi GP. Mineralocorticoid receptor antagonists: time of repositioning them in the treatment of arterial hypertension. J Hypertens. 2018;36:1015\u20138.","journal-title":"J Hypertens"},{"key":"139_CR16","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1210\/jc.2014-2788","volume":"99","author":"M Haase","year":"2014","unstructured":"Haase M, Riester A, Kropil P, Hahner S, Degenhart C, Willenberg HS, et al. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy. J Clin Endocrinol Metab. 2014;99:4397\u2013402.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41371-018-0139-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-018-0139-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-018-0139-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:23:28Z","timestamp":1684617808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-018-0139-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,5]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["139"],"URL":"https:\/\/doi.org\/10.1038\/s41371-018-0139-x","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"type":"print","value":"0950-9240"},{"type":"electronic","value":"1476-5527"}],"subject":[],"published":{"date-parts":[[2018,12,5]]},"assertion":[{"value":"24 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures that will be performed in the study are in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study will be started only after approval of the institutional Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}